| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Insider buying and selling activity across 114 companies in the Pharmaceuticals industry. Part of the Health Care sector.
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 13, 2023 | ETST Earth Science Tech, Inc. | Saumat Giorgio R. | Director, 10% Owner | Buy | 21,443 | $0.04 | $914.94 | - | - | - | |
| Feb 13, 2023 | LLY Eli Lilly & Co | White Anne E. | EVP &Pres, Lilly Neuroscience | Sell | 5,000 | $344.62 | $1,723,075.00 | -4.1% | +24.0% | +112.0% | |
| Feb 13, 2023 | COLL Collegium Pharmaceutical, Inc | Kuhlmann Shirley R.49 | EVP And General Counsel | Sell | 21,811 | $26.88 | $586,279.68 | -13.7% | -12.8% | +19.4% | |
| Feb 10, 2023 | UTHR United Therapeutics Corp | Rothblatt Martine A58 | Chairperson &CEO | Sell | 16,000 | $254.06 | $4,064,922.70 | -39.9% | -16.3% | -16.8% | |
| Feb 9, 2023 | MRK Merck & Co., Inc. | Mizell Steven52 | EVP, Chief Hr Officer | Sell | 5,000 | $107.00 | $535,006.50 | -12.5% | +11.2% | +20.8% | |
| Feb 9, 2023 | ETST Earth Science Tech, Inc. | Saumat Giorgio R. | Director, 10% Owner | Buy | 52,000 | $0.04 | $2,290.00 | - | - | - | |
| Feb 8, 2023 | UTHR United Therapeutics Corp | Rothblatt Martine A58 | Chairperson &CEO | Sell | 16,000 | $253.35 | $4,053,521.04 | -40.7% | -17.1% | -16.2% | |
| Feb 8, 2023 | NBIX Neurocrine Biosciences Inc | Cooke Julie59 | Chief Human Resources Officer | Sell | 17,079 | $102.76 | $1,755,121.31 | -9.6% | -6.9% | +28.6% | |
| Feb 8, 2023 | NBIX Neurocrine Biosciences Inc | Boyer David W.51 | Chief Corp. Affairs Officer | Sell | 25,238 | $102.49 | $2,586,741.39 | -46.8% | -6.9% | +28.6% | |
| Feb 8, 2023 | NBIX Neurocrine Biosciences Inc | Roberts Eiry49 | Chief Medical Officer | Sell | 16,525 | $102.74 | $1,697,706.70 | -10.8% | -6.9% | +28.6% | |
| Feb 8, 2023 | NBIX Neurocrine Biosciences Inc | Gorman Kevin Charles55 | Chief Executive Officer | Sell | 29,044 | $102.90 | $2,988,757.87 | -1.5% | -6.9% | +28.6% | |
| Feb 8, 2023 | NBIX Neurocrine Biosciences Inc | Gano Kyle54 | Chief Business Development Off | Sell | 17,004 | $102.79 | $1,747,919.93 | -3.4% | -6.9% | +28.6% | |
| Feb 8, 2023 | NBIX Neurocrine Biosciences Inc | Lippoldt Darin60 | Chief Legal Officer | Sell | 16,275 | $102.71 | $1,671,636.70 | -9.6% | -6.9% | +28.6% | |
| Feb 8, 2023 | NBIX Neurocrine Biosciences Inc | Benevich Eric62 | Chief Commercial Officer | Sell | 19,650 | $102.70 | $2,018,104.78 | -15.7% | -6.9% | +28.6% | |
| Feb 8, 2023 | NBIX Neurocrine Biosciences Inc | Lloyd-Smith Malcolm49 | Chief Integration Officer | Sell | 15,318 | $102.64 | $1,572,196.57 | -9.6% | -6.9% | +28.6% | |
| Feb 8, 2023 | NBIX Neurocrine Biosciences Inc | Abernethy Matt57 | Chief Financial Officer | Sell | 28,588 | $102.61 | $2,933,469.99 | -17.8% | -6.9% | +28.6% | |
| Feb 7, 2023 | NBIX Neurocrine Biosciences Inc | Onyia Jude54 | Chief Scientific Officer | Sell | 4,508 | $102.30 | $461,166.15 | -40.9% | -5.7% | +31.3% | |
| Feb 7, 2023 | OWPC One World Products, Inc. | McCabe John S | 10% Owner | Buy | 3,101,046 | $0.09 | $277,730.82 | +1.7% | - | - | |
| Feb 6, 2023 | BMY Bristol Myers Squibb Co | Powell Ann64 | EVP, Chief Human Resources | Sell | 11,183 | $74.69 | $835,258.27 | -32.7% | -8.2% | -33.9% | |
| Feb 6, 2023 | BMY Bristol Myers Squibb Co | Caforio Giovanni59 | Board Chair And CEO | Sell | 240,000 | $74.65 | $17,916,000.00 | -50.4% | -8.2% | -33.9% | |
| Feb 6, 2023 | MRK Merck & Co., Inc. | Mizell Steven52 | EVP, Chief Hr Officer | Sell | 4,436 | $104.25 | $462,473.41 | -10.0% | +14.6% | +25.4% | |
| Feb 6, 2023 | UTHR United Therapeutics Corp | Rothblatt Martine A58 | Chairperson &CEO | Sell | 16,000 | $256.04 | $4,096,605.67 | -25.8% | -17.5% | -15.8% | |
| Feb 3, 2023 | ETST Earth Science Tech, Inc. | Saumat Giorgio R. | Director, 10% Owner | Buy | 10,000 | $0.05 | $450.00 | - | - | - | |
| Feb 3, 2023 | MRK Merck & Co., Inc. | Zachary Jennifer | EVP, General Counsel | Sell | 75,436 | $103.17 | $7,782,762.29 | -58.3% | +14.8% | +26.2% | |
| Feb 3, 2023 | SUPN Supernus Pharmaceuticals, Inc. | Khattar Jack A.64 | President, CEO | Sell | 13,732 | $42.05 | $577,492.26 | -0.8% | -12.4% | -33.5% |
The blue line has two modes, toggled with the Relative and Absolute buttons:
Relative (default) shows cumulative industry performance with both the overall market and parent sector movements removed. When the line rises above 100, the industry is outperforming its sector; below 100 means underperforming. This is calculated using factor returns via weighted least squares (WLS) regression, isolating pure industry-specific behavior.
Absolute shows the total cumulative return of the industry including market and sector movement. This reflects what an investor actually experienced — an industry can show strong absolute gains even while underperforming its sector in relative terms.
Both views start at an index of 100. Other return drivers such as momentum, value, or size are deliberately retained in both modes, since these are part of what makes an industry behave the way it does and may reflect the conditions insiders are responding to.